These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26271675)

  • 1. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
    Proia DA; Smith DL; Zhang J; Jimenez JP; Sang J; Ogawa LS; Sequeira M; Acquaviva J; He S; Zhang C; Khazak V; Astsaturov I; Inoue T; Tatsuta N; Osman S; Bates RC; Chimmanamada D; Ying W
    Mol Cancer Ther; 2015 Nov; 14(11):2422-32. PubMed ID: 26271675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
    Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
    Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
    Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
    Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
    Gaponova AV; Nikonova AS; Deneka A; Kopp MC; Kudinov AE; Skobeleva N; Khazak V; Ogawa LS; Cai KQ; Duncan KE; Duncan JS; Egleston BL; Proia DA; Boumber Y; Golemis EA
    Clin Cancer Res; 2016 Oct; 22(20):5120-5129. PubMed ID: 27267850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
    Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
    Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
    Deneka AY; Haber L; Kopp MC; Gaponova AV; Nikonova AS; Golemis EA
    PLoS One; 2017; 12(4):e0176747. PubMed ID: 28453558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
    McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
    Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.
    Menezes DL; Taverna P; Jensen MR; Abrams T; Stuart D; Yu GK; Duhl D; Machajewski T; Sellers WR; Pryer NK; Gao Z
    Mol Cancer Ther; 2012 Mar; 11(3):730-9. PubMed ID: 22246440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
    Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
    J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
    Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
    Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors.
    Perino S; Moreau B; Freda J; Cirello A; White BH; Quinn JM; Kriksciukaite K; Someshwar A; Romagnoli J; Robinson M; Movassaghian S; Cipriani T; Wooster R; Bilodeau MT; Whalen KA
    Mol Cancer Ther; 2020 Aug; 19(8):1613-1622. PubMed ID: 32499300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
    Hoch U; Staschen CM; Johnson RK; Eldon MA
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
    Taddei M; Ferrini S; Giannotti L; Corsi M; Manetti F; Giannini G; Vesci L; Milazzo FM; Alloatti D; Guglielmi MB; Castorina M; Cervoni ML; Barbarino M; Foderà R; Carollo V; Pisano C; Armaroli S; Cabri W
    J Med Chem; 2014 Mar; 57(6):2258-74. PubMed ID: 24588105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.
    Nekkanti V; Venkateswarlu V; Ansari KA; Pillai R
    Curr Drug Deliv; 2011 Nov; 8(6):661-6. PubMed ID: 22313161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
    Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
    Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.